Royalty Pharma PLC $RPRX Stock Holdings Decreased by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG lessened its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 76.6% during the first quarter, HoldingsChannel.com reports. The firm owned 21,089 shares of the biopharmaceutical company’s stock after selling 68,946 shares during the period. J. Safra Sarasin Holding AG’s holdings in Royalty Pharma were worth $1,011,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of RPRX. Royal Bank of Canada increased its holdings in Royalty Pharma by 367.7% in the first quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after buying an additional 160,191 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Royalty Pharma by 20.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock valued at $2,490,000 after buying an additional 13,489 shares in the last quarter. Focus Partners Wealth acquired a new stake in Royalty Pharma during the first quarter valued at approximately $264,000. Intech Investment Management LLC lifted its holdings in Royalty Pharma by 41.0% during the 1st quarter. Intech Investment Management LLC now owns 47,992 shares of the biopharmaceutical company’s stock worth $1,494,000 after buying an additional 13,951 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in Royalty Pharma by 21.4% during the 2nd quarter. Invesco Ltd. now owns 1,559,378 shares of the biopharmaceutical company’s stock worth $56,184,000 after buying an additional 274,960 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Weiss Ratings downgraded Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. TD Cowen upped their price target on Royalty Pharma from $50.00 to $65.00 and gave the company a “buy” rating in a research report on Monday. Citigroup raised their price objective on Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley lifted their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a report on Friday, April 10th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $56.57.

Royalty Pharma Price Performance

NASDAQ RPRX opened at $55.67 on Wednesday. Royalty Pharma PLC has a 52 week low of $34.08 and a 52 week high of $58.84. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The stock has a market cap of $32.06 billion, a price-to-earnings ratio of 37.87, a price-to-earnings-growth ratio of 10.02 and a beta of 0.43. The company has a 50-day moving average price of $54.58 and a two-hundred day moving average price of $48.20.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. The company had revenue of $630.58 million for the quarter, compared to analysts’ expectations of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. Analysts forecast that Royalty Pharma PLC will post 5.17 EPS for the current year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were given a $0.235 dividend. This represents a $0.94 annualized dividend and a yield of 1.7%. The ex-dividend date was Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.

Insiders Place Their Bets

In other Royalty Pharma news, CFO Terrance P. Coyne sold 64,399 shares of Royalty Pharma stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total transaction of $3,476,258.02. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of the business’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the transaction, the director owned 191,803 shares of the company’s stock, valued at $10,165,559. This trade represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 427,800 shares of company stock worth $23,333,723 over the last 90 days. Insiders own 18.84% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.